Rani Therapeutics
RANI
34 hedge funds and large institutions have $11.8M invested in Rani Therapeutics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 6 closing their positions.
434% more call options, than puts
Call options by funds: $155K | Put options by funds: $29K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
10% more capital invested
Capital invested by funds: $10.7M → $11.8M (+$1.07M)
1.44% less ownership
Funds ownership: 13.26% → 11.82% (-1.4%)
8% less funds holding
Funds holding: 37 → 34 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$127K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$110K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$104K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$103K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$68.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
-$877K |
| 2 |
TPC
Takeda Pharmaceutical Company
Tokyo,
Japan
|
-$640K |
| 3 |
Renaissance Technologies
New York
|
-$252K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$169K |
| 5 |
ASGS
Alpha Square Group S
New York
|
-$104K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $11.2K | +$2.59K | +500 | +20% |
|
|
AF
27
Allworth Financial
Folsom,
California
| $9.61K | – | – | – |
|
28
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $7.6K | -$36.9K | -7,116 | -78% |
|
29
Simplex Trading
Chicago,
Illinois
| $5K | +$611 | +118 | +9% |
|
30
Belvedere Trading
Chicago,
Illinois
| $3.77K | +$5.13K | +991 | New |
|
31
RhumbLine Advisers
Boston,
Massachusetts
| $1.19K | – | – | – |
|
32
JP Morgan Chase
New York
| $270 | -$65.4K | -12,615 | -99% |
|
33
Qube Research & Technologies (QRT)
London,
United Kingdom
| $12 | – | – | – |
|
|
ASGS
34
Alpha Square Group S
New York
| – | -$104K | -33,401 | Closed |
|
|
HF
35
HRT Financial
New York
| – | -$70K | -22,587 | Closed |
|
|
CL
36
Choreo LLC
Rockford,
Illinois
| – | -$61.6K | -19,813 | Closed |
|
|
AWM
37
Activest Wealth Management
Aventure,
Florida
| – | -$50.8K | -9,800 | Closed |
|
38
Wells Fargo
San Francisco,
California
| – | -$320 | -103 | Closed |
|
39
Barclays
London,
United Kingdom
| – | -$121 | -39 | Closed |
|
RANI Hedge Fund Activity: Q2 2024 in Review
34 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q2 2024, worth a combined $11.8M — up 9.9% from $10.7M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of RANI and 3 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 10 added.
The largest buyer was Vanguard Group, adding an estimated $127K. The largest seller was United Services Automobile Association, cutting an estimated $877K.
- 34 institutional investors held Rani Therapeutics (RANI) as of Q2 2024, down from 37 in Q1 2024.
- Funds reported $11.8M of Rani Therapeutics stock for Q2 2024, up 9.9% quarter-over-quarter.
- 3 funds opened new Rani Therapeutics positions in Q2 2024 and 6 closed out, a net change of -3 holders.
- The largest Rani Therapeutics buyer in Q2 2024 was Vanguard Group, an estimated $127K added.
- The largest Rani Therapeutics seller in Q2 2024 was United Services Automobile Association, an estimated $877K sold.
Based on aggregated 13F filings for Q2 2024.